Tirzepatide Safety Profile
Safety information for tirzepatide including common side effects, warnings, and contraindications. Based on SURPASS and SURMOUNT clinical trial data with over 10,000 patient exposures.
Safety Overview
Tirzepatide has been evaluated in the SURPASS and SURMOUNT clinical trial programs with over 10,000 patient exposures.
Common Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Nausea | 12-18% | Transient, decreases over time |
| Diarrhea | 12-17% | Correlates with treatment intensity |
| Vomiting | 5-9% | More common during titration |
| Constipation | 6-7% | Less common than diarrhea |
| Decreased appetite | 5-10% | Part of mechanism |
| Dyspepsia | 5-8% | Indigestion symptoms |
Serious Warnings
Boxed Warning: Thyroid C-Cell Tumors
Rodent studies showed thyroid tumors. Clinical relevance to humans is uncertain but contraindicated in those at risk.
Other Serious Risks
- Pancreatitis — Rare but serious; discontinue if suspected
- Gallbladder disease — Increased with rapid weight loss
- Hypoglycemia — Increased risk with insulin or sulfonylureas
Who Should NOT Use Tirzepatide
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to tirzepatide
Special Populations
- Pregnancy: Not recommended
- Breastfeeding: Not recommended
- Pediatric: Not approved in children
- Renal impairment: Use with caution
This safety information is for educational purposes. Consult prescribing information and healthcare provider.
Sources & Citations
- 2
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.